Statin use in giant cell arteritis: A retrospective study

Journal of Rheumatology

Volumn 40, Issue 6, 2013, Pages 910-915

  Schmidt, Jean ^a,b,c   Kermani, Tanaz A ^a   Muratore, Francesco ^a,d   Crowson, Cynthia S ^a   Matteson, Eric L ^a,d   Warrington, Kenneth J ^a  

^a MAYO CLINIC   (United States)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Epidemiology; Giant cell arteritis; Hydroxymethylglutaryl coa reductases; Vasculitis

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; ARTERY DISEASE; ARTICLE; BLOOD CELL COUNT; BODY MASS; CASE CONTROL STUDY; CLAUDICATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; DYSLIPIDEMIA; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FEVER; GIANT CELL ARTERITIS; HEADACHE; HEART INFARCTION; HUMAN; HUMAN TISSUE; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; ONSET AGE; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RHEUMATIC POLYMYALGIA; SEX; SMOKING; VISUAL DISORDER; WEIGHT REDUCTION;

EPIDEMIOLOGY; GIANT CELL ARTERITIS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; VASCULITIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GIANT CELL ARTERITIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84878655723     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121150     Document Type: Article

References (30)

1. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009;203:325-30.
2. Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 2011;22:165-70.
3. Quist-Paulsen P. Statins and inflammation: An update. Curr Opin Cardiol 2010;25:399-405.
4. Ridker PM, Solomon DH. Should patients with rheumatoid arthritis receive statin therapy? Arthritis Rheum 2009;60:1205-9.
5. van Leuven SI, Mendez-Fernandez YV, Stroes ES, Tak PP, Major AS. Statin therapy in lupus-mediated atherogenesis: Two birds with one stone? Ann Rheum Dis 2011;70:245-8.
6. Willey JZ, Elkind MS. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010;67:1062-7.
7. Lodi S, Evans SJW, Egger P, Carpenter J. Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol 2010;69:85-94.
8. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
9. Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A, et al. Persistence with statins and onset of rheumatoid arthritis: A population-based cohort study. PLoS Med 2010;7:e1000336.
10. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45.
11. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011;63:633-9.
12. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Hajeer AH, Branas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine 2000;79:283-92.
13. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. Arthritis Rheum 2003;48:3522-31.
14. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev 2004;3:46-53.
15. Weyand CM, Younge BR, Goronzy JJ. IFN-gamma and IL-17: The two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 2011;23:43-9.
16. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
17. Melton LJ 3rd. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74.
18. Rosenbaum PR. Model-based adjustment. J Am Stat Assoc 1987;82:387-94.
19. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-81.
20. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 2010;58:1311-7.
21. Glasser SP, Wadley V, Judd S, Kana B, Prince V, Jenny N, et al. The Association of statin use and statin type and cognitive performance: Analysis of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Clin Cardiol 2010;33:280-8.
22. Duhaut P, Pinede L, Demolombe-Rague S, Loire R, Seydoux D, Ninet J, et al. Giant cell arteritis and cardiovascular risk factors - A multicenter, prospective case-control study. Arthritis Rheum 1998;41:1960-5.
23. Machado EBV, Gabriel SE, Beard CM, Michet CJ, O'Fallon WM, Ballard DJ. A population-based case-control study of temporal arteritis - Evidence for an association between temporal arteritis and degenerative vascular disease. Int J Epidemiol 1989;18:836-41.
24. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein - A meta-analysis. J Am Coll Cardiol 2007;49:2003-9.
25. Peters SAE, Palmer MK, Grobbee DE, Crouse JR, O'Leary DH, Raichlen JS, et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med 2010;268:155-61.
26. Hegg R, Lee AG, Tagg NT, Zimmerman MB. Statin or nonsteroidal anti-inflammatory drug use is associated with lower erythrocyte sedimentation rate in patients with giant cell arteritis. J Neuro-ophthalmol 2011;31:135-8.
27. Garcia-Martinez A, Hernandez-Rodriguez J, Grau JM, Cid MC. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum 2004;51:674-8.
28. Narvaez J, Bernad B, Nolla JM, Valverde J. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum 2007;36:322-7.
29. Kagami S, Owada T, Kanari H, Saito Y, Suto A, Ikeda K, et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. Int Immunol 2009;21:679-89.
30. Bu DX, Tarrio M, Grabie N, Zhang Y, Yamazaki H, Stavrakis G, et al. Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Invest 2010;120:1961-70.